Flucytosine dose requirements in a patient receiving continuous veno-venous haemofiltration [5]

Intensive Care Medicine

Volumn 28, Issue 7, 2002, Pages 999-

  Thomson, A H ^a   Shankland, G ^b   Clareburt, C ^c   Binning, S ^b  

^a WESTERN INFIRMARY   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c Octagon PCG   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; FLUCYTOSINE; ANTIMETABOLITE;

ADULT; CASE REPORT; CONTROLLED STUDY; CREATININE CLEARANCE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HEMOFILTRATION; HUMAN; KIDNEY DISEASE; LETTER; CHRONIC KIDNEY FAILURE; METHODOLOGY; RENAL REPLACEMENT THERAPY; SEPSIS; URINE;

ADULT; ANTIMETABOLITES; CASE REPORT; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUCYTOSINE; HEMOFILTRATION; HUMAN; KIDNEY FAILURE, CHRONIC; RENAL REPLACEMENT THERAPY; SEPSIS; HUMANS;

EID: 0036311638     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-002-1340-4     Document Type: Letter

References (5)

1. OPT: A package of computer programs for parameter optimization in clinical pharmacokinetics
2. Flucytosine: A review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions
3. 5-Fluorocytosine kinetics in patients with acute renal failure undergoing continuous hemofiltration
4. Elimination of flucytosine by continuous hemofiltration